AAV-Vectored Expression of Marburg Virus–Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad345 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Amira D Rghei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada. Hauptthemen laut MEDLINE: Marburgvirus, Marburg Virus Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Public Health Agency of Canada, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Although there are no approved countermeasures available to prevent or treat disease caused by Marburg virus (MARV), potently neutralizing monoclonal antibodies (mAbs) derived from B cells of human survivors have been identified. One such mAb, MR191, has been shown to provide complete protection against MARV in nonhuman primates. We previously demonstrated that prophylactic administration of an adeno-associated virus (AAV) expressing MR191 protected mice from MARV. Here, we modified the AAV-MR191 coding sequence to enhance efficacy and reevaluated protection in a guinea pig model. Remarkably, 4 different variants of AAV-MR191 provided complete protection against MARV, despite administration 90 days prior to challenge. Based on superior expression kinetics, AAV-MR191-io2, was selected for evaluation in a dose-reduction experiment. The highest dose provided 100% protection, while a lower dose provided ∼88% protection. These data confirm the efficacy of AAV-mediated expression of MR191 and support the further development of this promising MARV countermeasure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
- Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
- Avamab Pharma, Inc, Calgary, Alberta, Canada.
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.
ORCID-Profile: Logan Banadyga
Förderung
- CIHR
- Public Health Agency of Canada
- Canadian Institutes of Health Research
Zitieren
APA
Rghei, A. D., Cao, W., He, S., Lopes, J. A., Zielinska, N., Pei, Y., Thompson, B., Banadyga, L., & Wootton, S. K. (2023). AAV-Vectored Expression of Marburg Virus–Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad345
Vancouver
Rghei AD, Cao W, He S, Lopes JA, Zielinska N, Pei Y, et al. AAV-Vectored Expression of Marburg Virus–Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad345
BibTeX
@article{Rghei2023,
author = {Rghei, Amira D and Cao, Wenguang and He, Shihua and Lopes, Jordyn A and Zielinska, Nicole and Pei, Yanlong and Thompson, Brad and Banadyga, Logan and Wootton, Sarah K},
title = {AAV-Vectored Expression of Marburg Virus–Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad345}
}
EUVIMED